VectorY Announces Participation in Scientific Conferences in October 2022

AMSTERDAM, October 06, 2022--(BUSINESS WIRE)--VectorY Therapeutics, a biotech company focusing on the development of innovative gene therapy approaches for the treatment of neuro-degenerative and muscular disorders through vectorized antibodies, today announces participation in three upcoming conferences.

5th Annual ALS Research Symposium (ALS ONE), 6-7 & 11 October, virtually

  • Presentation title: Reduction of oxidized phospholipids or misfolded protein aggregates by AAV-VecTabs in an Amyotrophic Lateral Sclerosis pre-clinical models
    Presenter: Pavlina Konstantinova, Chief Scientific Officer
    Time and date: October 7, 14:05 ET

European Society of Gene & Cell Therapy (ESGCT) Annual Congress, 11-14 October, Edinburgh

  • Poster title: VecTrons: Targeting misfolded proteins in neurodegenerative diseases
    Presenter: Menno Spits, Scientist
    Poster number: P251
    Time and date: October 12, Poster Session 1,19:30-21:00 BST

  • Poster title: Generation and characterization of stable recombinant baculoviruses for large-scale production of rAAV
    Presenter: Hilde van Tongeren, Head of Vector Generation
    Poster number: P293
    Time and date: October 12, Poster Session 1, 19:30-21:00 BST

  • Poster title: VecTabs® and advanced human in-vitro models: targeting TDP-43 aggregates and oxidized phosphocholines in Amyotrophic lateral sclerosis
    Presenter: Andreia Duarte, Scientist
    Poster number: P353
    Time and date: October 12, Poster Session 1, 19:30-21:00 BST

  • Poster title: Next generation rAAV capsids show enhanced transduction efficiency in 2D and 3D human cellular models for neurodegenerative diseases
    Presenter: Carmen Gallego, Scientist, Vector Technologies
    Poster number: P056
    Time and date: October 13, Poster Session 2, 17:30-19:15 BST

2022 Cell & Gene Meeting on the Mesa, 11-13 October, Carlsbad, CA

  • Presentation title: Precision targeted gene therapies for CNS and neuromuscular disease
    Presenter: Barbara Sanders, Chief Technology Officer
    Time and date: October 13, 11:45 PT

To meet the VectorY team at any of these meetings, please contact


Notes to Editors

About VectorY
VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for neurodegenerative and muscular diseases with high unmet medical need such as amyotrophic lateral sclerosis (ALS) and Huntington’s disease.

VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics based on a novel AAV gene therapy platform, antibody-based targeted protein degradation technologies and proprietary manufacturing technology. While focusing initially on neurodegenerative and muscular diseases, VectorY's synergistic technologies may be applied across a wide range of indications.

VectoryY was founded in October 2020 and is based on the Amsterdam Science Park.

For more information, see

View source version on


VectorY B.V.
Sariette Witte, Head of Communications
Tel: +31 (20) 226 8020

Instinctif Partners (media enquiries)
Melanie Toyne-Sewell /Giulia Lasagni/ Manisha Kuttetira
Tel: +44 20 7457 2020